TScan Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the development of T cell receptor-engineered T cell therapies for the treatment of cancer, appointed Justin McCue, chief technology officer.

McCue joins TScan with over 20 years of experience in biologics and cell therapy manufacturing, including process/analytical development, technical operations, clinical development, and commercialization of T cell therapy products.

McCue joins TScan from Avectas, where he most recently served as chief technology officer responsible for leading technology development and scientific strategy. Prior to joining Avectas, McCue was vice president of technical operations at Repertoire Immune Medicines where he led CMC development and clinical manufacturing of their multi-targeted antigen-specific T-cell platform. Before this, McCue spent more than 15 years in the cell therapy and biopharma industry, including roles at Juno/Celgene and Biogen.

“We are delighted to welcome Justin to TScan,” said Gavin MacBeath, CEO. “His extensive expertise is a valuable addition to the company and an important next step in the evolution of our executive team. Justin’s experience with clinical and commercial manufacturing will be invaluable as we continue to advance our heme program through clinical development and launch our multi-TCR-T solid tumor program.”

McCue said, “I look forward to bringing my experience in the areas of technology development, technical operations, and commercial manufacturing readiness to TScan at this critical time in the company’s trajectory. I am excited to join a seasoned leadership team and support the company in its goal to deliver life-changing therapies to patients with heme malignancies and solid tumors.”